- Home
- NTRA vs CNP Comparison
NTRA vs CNP Comparison
Compare NTRA & CNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- CNP
- Stock Information
- Founded
- NTRA 2003
- CNP 1866
- Country
- NTRA United States
- CNP United States
- Employees
- NTRA N/A
- CNP N/A
- Industry
- NTRA Medical Specialities
- CNP Electric Utilities: Central
- Sector
- NTRA Health Care
- CNP Utilities
- Exchange
- NTRA Nasdaq
- CNP Nasdaq
- Market Cap
- NTRA 21.7B
- CNP 24.0B
- IPO Year
- NTRA 2015
- CNP N/A
- Fundamental
- Price
- NTRA $163.02
- CNP $38.12
- Analyst Decision
- NTRA Strong Buy
- CNP Buy
- Analyst Count
- NTRA 16
- CNP 13
- Target Price
- NTRA $193.50
- CNP $36.81
- AVG Volume (30 Days)
- NTRA 1.7M
- CNP 5.8M
- Earning Date
- NTRA 08-07-2025
- CNP 07-24-2025
- Dividend Yield
- NTRA N/A
- CNP 2.31%
- EPS Growth
- NTRA N/A
- CNP N/A
- EPS
- NTRA N/A
- CNP 1.43
- Revenue
- NTRA $1,964,250,000.00
- CNP $8,982,000,000.00
- Revenue This Year
- NTRA $19.98
- CNP $7.24
- Revenue Next Year
- NTRA $16.16
- CNP $3.93
- P/E Ratio
- NTRA N/A
- CNP $26.61
- Revenue Growth
- NTRA 44.38
- CNP 4.84
- 52 Week Low
- NTRA $110.57
- CNP $25.41
- 52 Week High
- NTRA $183.00
- CNP $39.39
- Technical
- Relative Strength Index (RSI)
- NTRA 65.28
- CNP 51.75
- Support Level
- NTRA $152.62
- CNP $38.04
- Resistance Level
- NTRA $161.92
- CNP $38.75
- Average True Range (ATR)
- NTRA 6.11
- CNP 0.62
- MACD
- NTRA 3.42
- CNP -0.09
- Stochastic Oscillator
- NTRA 93.78
- CNP 41.47
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About CNP CenterPoint Energy Inc (Holding Co)
CenterPoint Energy owns a portfolio of businesses. Its regulated electric utilities provide transmission and distribution services to more than 2.5 million customers in the Houston area, southern Indiana, and west central Ohio. The company has natural gas distribution systems serving approximately 4 million customers.